SECTION III: INTRODUCTION

THE OFFER

All references to the Selling Shareholders includes (a) the Investor Selling Shareholder, namely, PI Opportunities Fund — I;
and (b) the Other Selling Shareholders, namely, S. S. Pharma LLC, Natco Pharma Limited, Time Cap Pharma Labs Private
Limited, Shore Pharma LLC, A. Raghava Reddy, K Prakurthi, Navdeep Patyal, Sangeeta Raju, R. Venkat Reddy, TK Kurien,
Nithya Venkataramani, Atul Gupta, Manoj Jaiswal, Rahul Garg, Kollengode Ramanathan Lakshminarayana and Bijou Kurien

(collectively, the “Selling Shareholders”).

The following table sets forth details of the Offer:

 

Equity Shares Offered

 

Offer of Equity Shares

17,573,342* Equity Shares, aggregating to 213,982.95 million

 

of which:

 

Fresh Issue

7,544,511 Equity Shares aggregating to 26,000 million

 

Offer for Sale”)

10,028,831 Equity Shares aggregating to 27,982.95 million

 

Employee Reservation Portion ©

69,637 Equity Shares, aggregating to 250 million

 

Net Offer

17,503,705Equity Shares, aggregating to 13,932.96million

 

The Net Offer of which consists of:

 

QIB Portion®®

Not more than 8,751,852 Equity Shares aggregating to 26,966.47
million

 

of which:

 

(i) _ Anchor Investor Portion

5,251,111 Equity Shares

 

(ii) Net QIB Portion

3,500,741 Equity Shares

 

of which:

 

(iii) Mutual Fund Portion

175,038 Equity Shares

 

(iv) Balance for all QIBs including Mutual Funds

3,325,703 Equity Shares

 

Non-Institutional Portion

Not less than 2,625,556 Equity Shares aggregating to 22,089.94
million

 

 

Retail Portion

Not less than 6,126,297 Equity Shares aggregating to 24,876.53
million

 

 

Pre and post-Offer Equity Shares

 

Equity Shares outstanding prior to the Offer

111,761,165 Equity Shares

 

Equity Shares outstanding after the Offer

119,305,676 Equity Shares

 

 

Use of Net Proceeds of the Offer

 

 

See “Objects of the Offer” on page 103 for information about the use
of the proceeds from the Fresh Issue. Our Company will not receive
any proceeds from the Offer for Sale.

 

 

“Subject to finalisation of the Basis of Allotment.

© The Offer has been authorised by our Board of Directors pursuant to the resolution passed at the meeting dated August 3, 2021 and the Fresh Issue has
been approved by our Shareholders pursuant to the resolution passed at their meetings dated August 5, 2021.

e

The Selling Shareholders have severally and not jointly confirmed and approved their participation in the Offer for Sale as set out below:

 

 

Ss. Selling Shareholder | Number of Equity Shares* offered in the Offer | Date of consent letter ‘Date of corporate action /
No. for Sale board resolution / power of
attorney
Investor Selling Shareholder

 

1. |Pl Opportunities Fund I | 7,826,626 Equity Shares aggregating to
6,230.00 million

‘August 4, 2021 and as amended] July 5, 2021 and November
pursuant to the consent letter 22, 2021
dated November 27, 2021

 

Other Selling Shareholders

 

2. |S.S. Pharma LLC 1,344,221 Equity Shares
21,070.00 million

aggregating to | July 30, 2021 and as amended July 19, 2021

pursuant to the consent letter
dated November 24, 2021

 

3. | Shore Pharma LLC
million

402,010 Equity Shares aggregating to %320.00 | July 30, 2021 and as amended July 19, 2021

pursuant to the consent letter
dated November 24, 2021

 

 

 

 

 

 

 

million

 

pursuant to the consent letter
dated November 26, 2021

 

4. | Natco Pharma Limited 125,628 Equity Shares aggregating to 2100.00 | August 5, 2021 June 17, 2021
million
5. |Time Cap Pharma Labs | 125,628 Equity Shares aggregating to 2100.00 | August 5, 2021 July 1, 2021
Private Limited million
6. |A. Raghava Reddy 89,547 Equity Shares aggregating to %71.28 | August5, 2021 and as amended ‘August 3, 2021
million pursuant to the consent letter
dated November 26, 2021
7. | K Prakurthi 53,115 Equity Shares aggregating to %42.28 | August 5, 2021 and as amended ‘August 2, 2021

 

 

57
